However, the use of SGLT2 inhibitors in type 1 diabetes is associated with an increased risk of diabetic ketoacidosis, a serious and potentially life-threatening complication [2, 3]. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.